Francesco Passamonti

61PUBLICATIONS
355CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Gene and molecular therapyImmunogenetics (incl. genetic immunology)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (61)

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|Jun 02, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

|May 07, 2026
Adding transcriptomic features to MF prognostic models.

|Apr 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

|Mar 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Paola Guglielmelli, Massimo Breccia, Francesco Mendicino

|Mar 05, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, Francesca Palandri, Paola Guglielmelli

Pageof 11

Frequent Collaborators

12 joint publications

Francesca Palandri

12 joint publications

Michele Merli

11 joint publications

Paola Guglielmelli

9 joint publications

Francesco Marchesi